Dobrin Nedelkov
Intrinsic LifeSciences (United States), Arizona State University
Papers
5
Total Citations
317
H-Index
5
About
Dobrin Nedelkov is a pioneering researcher in the field of mass spectrometric immunoassay (MSIA) technology, dedicated to advancing high-throughput protein characterization and quantification directly from biological fluids. His work has fundamentally shaped how researchers and clinicians measure critical biomarkers, combining the specificity of immunoaffinity capture with the analytical power of mass spectrometry. Nedelkov's most influential contributions center on the development and refinement of MSIA platforms capable of processing hundreds to thousands of samples daily. His landmark 2001 study on β-2 microglobulin detection (85 citations) introduced a 96-well robotic format using antibody-derivatized affinity pipettes, transforming protein analysis throughput. Building on this, his quantitative work on insulin-like growth factor 1 (IGF-1), cited 77 times, established rigorous methods for plasma protein quantification that have become foundational in clinical biomarker research. His 2014 study further scaled IGF-1 analysis to exceed 1,000 samples per day, directly addressing barriers to clinical adoption of MS-based diagnostics. His extension of MSIA to resistin expression profiling demonstrates his commitment to broadening the technology's biomedical applications. With over 300 cumulative citations across his key works, Nedelkov's research continues to bridge analytical chemistry and clinical proteomics in meaningful, practical ways.
Research Focus
Key Achievements
Top Papers
- 1
- 2Quantitative Mass Spectrometric Immunoassay of Insulin Like Growth Factor 177 citations · 2004
- 3
- 4
- 5